Editorial

摘要

Dear Readers, Innovative drug approval pathways are the order of the day. In the US, the Food and Drug Administration has granted its first "breakthrough therapy" designations - for two experimental cystic fibrosis treatments - under a new programme designed to expedite the development and review processes for medicines intended to treat serious or life-threatening diseases.The scheme joins an already busy mix of expedited drug development and review programmes in the US - fast track, priority review and accelerated approval.